Phase 3 Rheumatoid Arthritis Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who have active, disabling rheumatoid arthritis (a disease score meeting specific thresholds) even after trying a TNF-inhibitor biologic medication, or who had to stop that medication because of side effects or intolerance
- People who, if taking steroid medications (low dose) or anti-inflammatory drugs, have been on a stable dose for at least 2 weeks before joining the trial
- People whose insurance plan or financial assistance program covers at least one medication from each of the two treatment groups being studied in the trial
- People who have been taking certain traditional rheumatoid arthritis medications (such as methotrexate, sulfasalazine, hydroxychloroquine, or leflunomide) for at least 3 months and on a stable dose for at least 4 weeks may be able to continue these during the trial
Who may not be able to join:
- People who have previously been treated with more than three biologic medications in total
- People who have previously used a targeted synthetic DMARD (a specific newer class of rheumatoid arthritis tablet — confirm with trial site if unsure which medications this includes)
- People who have used leflunomide, sulfasalazine, cyclosporine, or azathioprine within the 2 months before joining the trial
- People who have had reactions or sensitivities to all four non-TNF biologic medications and also to targeted synthetic DMARDs
- People who have received a steroid injection (into a vein, muscle, or joint) within 1 month before joining the trial
- People who have received a live vaccine within 90 days before joining the trial
- People who have had a serious infection requiring hospital admission or intravenous antibiotics within the past month, or oral antibiotics within the past 2 weeks (including tuberculosis, severe bacterial infections, or invasive fungal infections)
- People with a history of HIV or any serious opportunistic infection
- People with more severe heart failure (classified as New York Heart Association Class III or IV — confirm with trial site)
- People who have latent (inactive) tuberculosis that has not yet been treated with anti-tuberculosis medication
- People with untreated Hepatitis B or Hepatitis C infection
- People with a history of deep vein thrombosis (blood clots in the legs) or pulmonary embolism (blood clots in the lungs)
- People who are pregnant or breastfeeding
- People who have had a herpes zoster (shingles) episode in the past 12 months and have not since received the shingles vaccine
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Jasvinder Singh, MD, University of Alabama at Birmingham
Phone: 205-975-2405
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Functional Limitation
Can't join this trial?
Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.